Salarius Pharmaceuticals, Inc. - Bathi operasional EBITDA SLRX

EBITDA volatility illustrates the current capital restructuring of Salarius Pharmaceuticals (SLRX) and the priority placed on mid-stage trials. The value 0.00 expresses the current value of the metric. The business relies on a virtual manufacturing model utilizing third-party contractors in the US. Profit potential is driven by multi-year patents in epigenetic therapy aimed at developing targeted anti-tumor drugs.

Conservative capital requires a transparent assessment of operational efficiency to minimize drawdown risks. This indicator measures real cash flow from core operations before deducting depreciation and the cost of borrowed capital, which is critical under tight monetary policy. Given the non-cyclical nature of targeted oncology therapy and the independence of research and development from GDP, the calculated EBITDA of Salarius Pharmaceuticals (SLRX) demonstrates the resilience of the company's fundamental metrics to macroeconomic shocks.